Core Points - Sichuan Mianzhu Nongke Shengyuan Biotechnology Co., Ltd. has been established with a registered capital of 2 million RMB [1] - The legal representative of the company is Shi Wenwei [1] - The company's business scope includes technology services, development, consulting, and promotion, as well as sales of food additives, biological materials, fertilizers, and import/export activities [1] Business Scope - General projects include technology services, development, consulting, and promotion [1] - Sales of food additives, biological materials, fertilizers, and import/export of goods [1] - Licensed projects include production of food additives, feed additives, fertilizers, and road transportation of goods (excluding hazardous materials) [1]

Group 1 - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives product ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the hottest industries in the capital market, driven by technological innovation and global healthcare demand [1] Group 2 - Since the introduction of Chapter 18A in 2018, which allows unprofitable biotechnology companies to list in Hong Kong, 78 companies have successfully gone public, raising approximately 131.64 billion HKD [2] - The total market capitalization of these 18A companies has reached nearly 1.5 trillion HKD, covering key areas such as antibodies, small molecules, vaccines, and innovative medical devices [2] - Institutional investors' holdings in the top 30 Hong Kong-listed healthcare companies have increased from 13.3 billion USD in 2017 to 43 billion USD by June 30, 2025, with the biotechnology sector particularly favored [2] Group 3 - In the first half of 2025, the healthcare sector in Hong Kong completed 27 refinancing activities, raising a total of 3.9 billion USD, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - The Hong Kong stock market has seen significant performance from healthcare stocks, especially 18A companies, with 27 out of 260 healthcare companies experiencing over 200% increase in stock prices this year [3] - Among the top 20 companies with the highest first-day stock price increases in the Hong Kong IPO market this year, 9 are healthcare companies, with 6 of them seeing increases over 100% [3]

| 国民经济行业分类 | 国际标准分类 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | > | | 标准编号 ▼ | | | | 捜索 | | 高级搜索 | | | A 农、林、牧、渔业 | | 标准列表 | | | | | | | | | B 采矿业 | | 序号 | 团体名称 | 标准编号 | 标准名称 | 公布日期 | 状态 | 详细 | 购买信 | | C 制造业 | | | | | | | | | 島 | | D 电力、热力、燃气及水生产和供应 | | | ** | T/CIET 1679 | 单分子完位超分辨 | | | | 不可出 | | नार | | 1 | 技术合作促进 | | | 2025-09-08 | 现行 | 详细 | | | | | | 会 | -2025 | 显微成像技术规范 | | | | 星 | | E 建筑业 | | | | | | | | | | 填补行业空白，推动SMLM技术迈向标准化时代 作为分辨率最高的超分辨成像技术，单分子定位超分辨成像已成为解析生 ...

Core Insights - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the fastest-growing industries in Hong Kong's capital market since the listing reforms in 2018, with over 260 biotechnology and healthcare companies now listed, totaling a market capitalization of over HKD 4.8 trillion [1][2] Group 1: Market Developments - The introduction of the 18A listing rule in 2018 allowed unprofitable biotechnology companies to list in Hong Kong, marking a significant turning point for the healthcare market [2] - As of October 13, 2023, 78 18A companies have successfully listed, raising approximately HKD 131.64 billion, with a total market capitalization of nearly HKD 1.5 trillion [2] - Institutional investors' holdings in the top 30 healthcare companies in Hong Kong increased from USD 13.3 billion in 2017 to USD 43 billion by June 30, 2025, with the biotechnology sector particularly favored [2] Group 2: Financing and Performance - In the first half of 2025, the healthcare sector completed 27 refinancing activities, raising a total of USD 3.9 billion, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - The Hong Kong stock market has seen significant gains in healthcare stocks, especially among 18A companies, with 27 companies experiencing over 200% increase in share price this year [3] - In 2025, 10 healthcare companies went public in Hong Kong, raising USD 2.1 billion, with an average first-day increase of 30.4%, making Hong Kong the leading market for healthcare IPO financing globally [2][3] Group 3: Notable Stock Performances - The top-performing healthcare stocks in Hong Kong have shown remarkable growth, with several companies experiencing increases exceeding 200% year-to-date [4] - Among the top 20 companies with the highest first-day price increases, 9 are healthcare companies, with 6 of them seeing increases over 100% [4][5]

Core Insights - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the hottest industries in the capital market, driven by technological innovation and global healthcare demand [1] Group 1: Market Development - Since the listing reform in 2018, the biotechnology and healthcare sectors have rapidly developed in Hong Kong, with over 260 companies listed, totaling a market capitalization of over HKD 4.8 trillion, up from approximately HKD 1.2 trillion at the end of 2018 [1] - The introduction of Chapter 18A in the listing rules allowed unprofitable biotechnology companies to list, marking a key turning point for the healthcare market [2] - As of October 13, 2023, 78 Chapter 18A companies have successfully listed, raising approximately HKD 131.64 billion, with a total market capitalization of nearly HKD 1.5 trillion [2] Group 2: Investment Trends - Institutional investors have significantly increased their holdings in the top 30 healthcare companies listed in Hong Kong, from USD 13.3 billion in 2017 to USD 43 billion by June 30, 2025 [2] - The biotechnology sector is particularly favored, with institutional investors holding 34% of the sector's market capitalization as of mid-2025 [2] - In the first half of 2025, 10 healthcare companies went public in Hong Kong, raising USD 2.1 billion, with an average first-day increase of 30.4%, making Hong Kong the leading market for healthcare IPO financing globally [2] Group 3: Performance of Healthcare Stocks - The refinancing activities in the healthcare sector have been robust, with 27 refinancing transactions completed in the first half of 2025, totaling USD 3.9 billion, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - Among the 260 healthcare companies, 27 have seen their stock prices increase by over 200% this year, with most being Chapter 18A companies [3] - The performance of healthcare stocks in the IPO market has been notable, with 9 out of the top 20 companies by first-day gains being healthcare firms, and 6 of them achieving gains over 100% [4]

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives ecosystem and provide investors with effective risk management tools in the rapidly growing biotechnology sector [1]. Group 1: Market Development - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of 30 major biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1]. - Since the listing reform in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries in Hong Kong's capital market, with over 260 companies listed and a total market capitalization exceeding HKD 4.8 trillion, quadrupling from approximately HKD 1.2 trillion at the end of 2018 [1]. Group 2: 18A Companies - The introduction of Chapter 18A in the listing rules in 2018 allowed unprofitable biotechnology companies to list in Hong Kong, marking a significant turning point for the healthcare market [2]. - As of October 13, 2023, 78 18A companies have successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 131.64 billion and achieving a total market capitalization of nearly HKD 1.5 trillion, covering key areas such as antibodies, small molecules, vaccines, innovative medical devices, surgical robots, and cell therapies [2]. Group 3: Institutional Investment - The development of the healthcare sector in Hong Kong has been supported by a diverse group of investors, including international investment institutions, healthcare funds, and mainland Chinese capital [2]. - According to Refinitiv, the total holdings of institutional investors in the top 30 Hong Kong-listed healthcare companies increased from USD 13.3 billion in 2017 to USD 43 billion by June 30, 2025, with the biotechnology sector particularly favored, accounting for 34% of institutional holdings in the Hong Kong biotechnology sector as of mid-2025 [2]. Group 4: Financing Activities - The healthcare sector has seen active refinancing activities, with 27 refinancing transactions completed in the first half of 2025, totaling USD 3.9 billion, surpassing the total refinancing amounts for the years 2022, 2023, and 2024 [3]. - The Hong Kong stock market has witnessed significant stock price increases in the healthcare sector, especially among 18A companies, with 27 out of 260 healthcare companies experiencing price increases exceeding 200% year-to-date [3]. Group 5: IPO Performance - In the first half of 2025, 10 healthcare companies went public in Hong Kong, raising USD 2.1 billion, with an average first-day increase of 30.4%, making Hong Kong the market with the highest new healthcare stock financing globally [2]. - Among the top 20 companies with the highest first-day price increases, 9 were healthcare companies, with 6 of them seeing increases of over 100% [4].

仲秋时节，山东泰安高新区的项目建设现场一片火热，到处都是蓬勃发展的景象。今年以来，泰安高新 区紧紧围绕新型工业化强市战略，把项目建设作为经济发展的"强引擎"，全力以赴抓项目、扩投资、促 发展，全区项目建设呈现出如火如荼的发展态势。一个个重大项目加速落地、拔节生长，为高质量发展 注入源源不断的动力。 在人工智能上甄机器人及发酵食品高端装备项目现场，施工人员争分夺秒，全力冲刺"当年建设、当年 投产"目标。该项目由中科恒信智能科技（泰安）有限公司投资建设，其核心产品"仿人上甑机器人"技 术达到国内领先水平，将为传统酿造行业注入智能化新动能。项目负责人王一雷介绍："我们配备了先 进的汽车吊和高空曲臂车协同作业，其中，高空曲臂车凭借灵活多变的机械臂，可实现360度全方位伸 展旋转，搭配智能防倾斜系统、紧急制动装置等安全配件，极大提升了高空效率和安全保障。项目团队 通过科学统筹、工序交叉和资源优化，确保建设高速推进。" 这些项目的顺利推进，让高新区的产业发展更加多元化、高端化，产业集聚效应也日益凸显。推进过程 中，高新区不断强化组织领导，主动靠上服务，深入施工现场，在工程验收、材料检验、安全生产、交 通运输、图纸审批方面 ...

天眼查App显示，近日，日照鑫农生物科技有限公司成立，法定代表人为张永昌，注册资本3万人民 币，经营范围为一般项目：生物有机肥料研发；生物农药技术研发；海洋生物活性物质提取、纯化、合 成技术研发；复合微生物肥料研发；土壤污染治理与修复服务；农业科学研究和试验发展；农林废物资 源化无害化利用技术研发；农副产品销售；生物基材料技术研发；肥料销售；生物饲料研发；饲料添加 剂销售；发酵过程优化技术研发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广； 畜牧渔业饲料销售；生物质能技术服务；林业有害生物防治服务；农林牧渔业废弃物综合利用；水生植 物种植；灌溉服务；工程和技术研究和试验发展；农业面源和重金属污染防治技术服务；农业园艺服 务；互联网销售（ 除销售需要许可的商品）；农作物秸秆处理及加工利用服务；生物基材料销售；食 品添加剂销售；人体干细胞技术开发和应用；医学研究和试验发展；饲料原料销售；细胞技术研发和应 用；农作物栽培服务。（ 除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目： 肥料生产；饲料添加剂生产；农药零售。（依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目 ...

Core Viewpoint - The acquisition of 51% stake in Shanghai Haowei Technology by Kangwei Century for 12.75 million yuan is a strategic move to enhance its capabilities in the molecular diagnostics and multi-omics service sectors, marking a significant step towards fourth-generation gene sequencing technology and precision medical services [2][4][14] Transaction Details - The acquisition price is set at 12.75 million yuan, funded by the company's own resources, which will not significantly impact daily operations [3] - After the acquisition, Kangwei Century will hold 51% of Haowei Technology, while Tianhao Biotechnology retains 49% [3] Performance Targets and Risks - Haowei Technology is committed to achieving over 20% revenue growth in 2025; failure to meet this target may trigger a compensation mechanism for Kangwei Century [4] - Potential risks include uncertainties in agreement execution, increased management costs during integration, and changes in industry policies [4] Market Environment - The molecular diagnostics market in China has been growing rapidly, with a projected market size of 50 billion yuan in 2024 and expected to exceed 150 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of over 20% [5] - The multi-omics integration analysis market is expected to grow even faster, with a CAGR of 30% [5] - Domestic companies are gaining market share by offering lower prices and faster service delivery compared to international giants [5] Company Overview: Kangwei Century - Established in 2007, Kangwei Century specializes in molecular detection enzyme raw materials and diagnostic kits, with a strong focus on independent technology development [8] - The company has launched over 700 products, breaking international monopolies in several niche areas [8] - Kangwei Century is advancing towards fourth-generation nanopore sequencing technology, aiming for scalable production and application in both research and clinical settings [8] Company Overview: Haowei Technology - Founded in 2024, Haowei Technology focuses on microbiome detection, multi-omics analysis, and bioinformatics services, targeting research institutions and biopharmaceutical companies [9][10] - The company achieved 8 million yuan in revenue in 2024, with service accuracy exceeding 95% and a 30% reduction in service delivery time [10] Synergistic Effects - The acquisition is part of Kangwei Century's strategy of combining internal research and external acquisitions, aiming to enhance its service capabilities across various disease areas [11] Future Outlook - The acquisition positions Kangwei Century to enter the multi-omics research service market, strengthening its overall presence in the molecular diagnostics industry [14] - The company anticipates a 25% revenue growth and a net profit margin increase to 22% by 2025, driven by the rising demand for precision medicine [14] - The integration of multi-omics and fourth-generation sequencing technologies is expected to create a competitive edge for domestic companies against imported products [14]

天眼查App显示，近日，合肥赫娜雅生物科技有限公司成立，法定代表人为吴一凡，注册资本10万人民 币，经营范围为一般经营项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；货 物进出口；技术进出口；化妆品零售；化妆品批发；个人卫生用品销售；消毒剂销售（不含危险化学 品）；日用百货销售；美发饰品销售；企业管理咨询；日用杂品销售；软件开发；广告制作；广告发 布；生物质能技术服务；市场营销策划；企业形象策划；品牌管理；信息技术咨询服务；第二类医疗器 械销售；生物基材料技术研发；个人互联网直播服务（除许可业务外，可自主依法经营法律法规非禁止 或限制的项目）。 ...